|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1981-05-01 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase IIa: single ascending dose safety, tolerability and pharmacokinetic study of NicaPlant® in aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping
A Phase IIb: Randomised, Single-Blind, Safety, Tolerability, Efficacy and Pharmacokinetic Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping
This study of NicaPlant® is conducted in patients who have a subarachnoid haemorrhage. Patients will be randomized in two treatment groups. Both groups will receive the standard of care and the investigational group will receive in addition NicaPlant®. NicaPlant® is tested to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).
100 项与 BIT Pharma GmbH 相关的临床结果
0 项与 BIT Pharma GmbH 相关的专利(医药)
100 项与 BIT Pharma GmbH 相关的药物交易
100 项与 BIT Pharma GmbH 相关的转化医学